Lifecore Biomedical experienced a 4% decrease in Q4 2025 revenue to $36.4 million, primarily due to lower CDMO development revenue, though HA manufacturing revenue increased. The company significantly reduced its net loss to $1.1 million from $7.1 million in the prior year, driven by a gain from a legacy business obligation settlement and favorable debt derivative adjustment. For the full fiscal year, revenue reached $128.9 million, meeting guidance, but the company reported a net loss of $38.7 million.

Lifecore posted a net loss of $14.8M in Q3 2025 on revenues of $35.2M. The company advanced its growth plans with new customer agreements and monetized unused equipment to strengthen its balance sheet.

Lifecore Biomedical reported strong revenues of $32.6 million for the second quarter of fiscal 2025, an 8% increase compared to the prior year. Gross margins improved, and the company signed multiple new project agreements. The balance sheet was strengthened through equity financing and restructuring of the credit facility.

Lifecore Biomedical reported a revenue increase of $0.2 million compared to the same period last year, driven by HA manufacturing revenues, but experienced a net loss of $16.2 million, which is higher than the net loss of $10.8 million in the comparable period of 2023. The company signed four new customers and multiple expansion agreements and successfully closed a $24.3 million private placement. They also reaffirmed their fiscal year 2025 revenue guidance of $126.5 to $130 million and Adjusted EBITDA guidance of $19 to $21 million.

Lifecore Biomedical reported a strong Q4 2024 with a 21.6% increase in revenue and a 122.0% increase in gross profit. The company is focused on maximizing its base business, advancing its development portfolio, and attracting new business.

Lifecore Biomedical reported a 12.2% increase in consolidated revenues to $31.5 million for the fourth quarter of fiscal year 2023. However, the company experienced a net loss of $33.8 million, which included a $23.8 million loss on debt refinancing and $6.8 million in restructuring and other non-recurring charges. The company finalized its transition to a stand-alone life sciences company with divestitures and a strategic refinancing and supply agreement with Alcon.

Lifecore Biomedical reported a decrease in consolidated revenues by 26.2% year-over-year to $27.6 million and a net loss from continuing operations of $15.5 million, which includes $8.9 million of restructuring and other non-recurring charges. The company removed its going concern qualification due to new financing.

Lifecore Biomedical reported a decrease in consolidated revenues by 10.7% year-over-year, with a net loss from continuing operations of $12.4 million. The company also announced its intention to explore strategic alternatives to maximize value for stockholders.

Landec Corporation reported a 4.1% increase in consolidated revenues, driven by an 8.0% increase in Lifecore segment revenues. The company is progressing with its strategy to divest Curation Foods assets and focus on Lifecore CDMO business.

Landec Corporation reported a 6.0% increase in consolidated revenues for Q4 2022, driven by growth in both Lifecore and Curation Foods segments. However, the company experienced a net loss due to a non-cash goodwill and intangibles impairment charge and restructuring costs, despite an increase in Lifecore segment adjusted EBITDA.

Landec Corporation reported an 18.8% increase in revenues, driven by a 27.9% increase in Lifecore segment revenues. The company's net loss from continuing operations was $7.1 million, which includes $4.6 million of restructuring and other non-recurring charges. The company is reiterating its previously announced guidance on a pro forma consolidated basis, and at the segment level.

Landec Corporation reported a net loss of $38.4 million for the second quarter of fiscal year 2022. However, pro forma revenues increased by 8.8% year-over-year, and pro forma adjusted EBITDA increased by 41.3% year-over-year. The company also closed the sale of its Eat Smart fresh packaged salads and vegetables business for $73.5 million in cash.

Landec Corporation reported a decrease in revenues by 5.1% to $128.8 million, but an increase in gross profit by 7.2% to $17.5 million for the first quarter of fiscal year 2022. The company's adjusted EBITDA increased by 42% to $4.4 million. The company reiterates its full year fiscal 2022 guidance.

Landec Corporation reported a decrease in revenues for the fourth quarter of fiscal year 2021, but an increase in gross profit. The net loss improved compared to the prior year period. Lifecore Biomedical showed revenue growth, while Curation Foods experienced a revenue decrease but improved gross margin.

Landec Corporation reported a decrease in revenues of 9.9% year-over-year, but adjusted EBITDA increased by 13%. Lifecore Biomedical's revenue grew, while Curation Foods faced COVID-19 headwinds.

Landec Corporation reported a decrease in revenues but an increase in gross profit for the second quarter of fiscal year 2021. The company's net loss increased due to restructuring charges and a change in the fair market value of its Windset investment. However, adjusted EBITDA significantly improved, driven by both the Curation Foods and Lifecore segments.

Landec Corporation reported a decrease in revenues but an increase in gross profit and adjusted EBITDA for the first quarter of fiscal year 2021. The company is focused on improving its balance sheet, investing in innovation, and optimizing operations.

Landec Corporation reported a 2.2% increase in revenue to $156.1 million for the fourth quarter of fiscal year 2020. However, the company experienced a net loss of $15.1 million, which included $6.8 million in restructuring and non-recurring charges, net of tax, and $9.6 million in impairment of goodwill and intangibles charges, net of tax.

Landec Corporation reported a decrease in revenues and gross profit for the third quarter of fiscal 2020, with revenues at $152.9 million and gross profit at $20.0 million. The company experienced a net loss of $11.5 million, which includes $12.7 million of restructuring and other non-recurring charges, net of tax. Adjusted EBITDA was $6.8 million, excluding $16.8 million of restructuring and other non-recurring charges.